Ocular Therapeutix (NASDAQ: OCUL) awards RSUs and options to CLO exec

Rhea-AI Filing Summary

Ocular Therapeutix Chief Legal Officer Todd Anderman reported new equity awards. On January 2, 2026, he received 64,900 restricted stock units (RSUs), each representing one share of common stock, at a price of $0. These RSUs vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining shares vesting in equal annual installments thereafter, subject to continued service.

On the same date, he was also granted a stock option for 197,650 shares of common stock with an exercise price of $11.82 per share and expiration on January 1, 2036. The option vests over four years, in monthly installments of 1/48 of the total starting one month after the grant date. After these transactions, he beneficially owned 152,468 shares of common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderman Todd

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		64,900(1)	A	$0	152,468	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.82	01/02/2026		A		197,650		(2)	01/01/2036	Common Stock	197,650	$0	197,650	D

Explanation of Responses:

1. On January 2, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter.

2. Subject to the reporting person's continued service to the Corporation, the shares underlying this option vest over four years, vesting 1/48 monthly beginning on the one-month anniversary of the date of grant.

	/s/ Todd Anderman	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did OCUL Chief Legal Officer Todd Anderman report?

Todd Anderman reported awards of 64,900 RSUs of common stock and a stock option for 197,650 shares with an exercise price of $11.82 per share, both granted on January 2, 2026.

How do the new OCUL restricted stock units for Todd Anderman vest?

The 64,900 RSUs vest over three years, with 1/3 vesting on the one-year anniversary of the January 2, 2026 grant and the remaining shares vesting in equal annual installments, subject to continued service.

What are the terms of the OCUL stock options granted to Todd Anderman?

He received a stock option for 197,650 shares of common stock with an exercise price of $11.82 per share, vesting over four years at 1/48 of the shares monthly beginning one month after the grant date, and expiring on January 1, 2036.

Did Todd Anderman buy or sell any existing OCUL shares in this Form 4?

The Form 4 reports grants of RSUs and stock options at a price of $0 per unit; it does not report open-market purchases or sales of existing shares.

How many OCUL common shares did Todd Anderman own after these grants?

Following the reported transactions, Todd Anderman beneficially owned 152,468 shares of Ocular Therapeutix common stock directly.

What role does the reporting person hold at Ocular Therapeutix (OCUL)?

The reporting person, Todd Anderman, serves as Chief Legal Officer of Ocular Therapeutix, Inc.